What is the recommended dose for the hepatitis B (HBV) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hepatitis B Vaccine Dosing

The recommended dose of hepatitis B vaccine varies by age, product, and clinical situation: for adults ≥20 years, standard dosing is either Engerix-B 20 μg (1.0 mL) or Recombivax HB 10 μg (1.0 mL) in a 3-dose series at 0,1, and 6 months, or alternatively Heplisav-B 20 μg (0.5 mL) in a 2-dose series at 0 and 1 month. 1

Standard Adult Dosing (Age ≥18-20 years)

Traditional 3-Dose Vaccines:

  • Engerix-B: 20 μg (1.0 mL) per dose at 0,1, and 6 months 1, 2
  • Recombivax HB: 10 μg (1.0 mL) per dose at 0,1, and 6 months 1
  • PreHevbrio: 10 μg (1.0 mL) per dose at 0,1, and 6 months 1

Accelerated 2-Dose Vaccine:

  • Heplisav-B: 20 μg (0.5 mL) per dose at 0 and 1 month (adults ≥18 years only) 1
  • This achieves approximately 90% seroprotection compared to 70.5-90.2% with Engerix-B 1

Adolescent Dosing (Ages 11-19 years)

  • Recombivax HB (ages 11-15): 10 μg (0.5 mL) in either a 2-dose schedule at 0 and 4-6 months OR a 3-dose schedule at 0,1, and 6 months 1
  • Engerix-B (ages 11-19): 10 μg (0.5 mL) per dose in a 3-dose schedule at 0,1, and 6 months 1, 2

Pediatric Dosing (Ages 6 months to 10 years)

  • Engerix-B: 10 μg per dose at 0,1, and 6 months 2
  • This produces 98% seroprotection 1-2 months after the third dose with a GMT of 4,023 mIU/mL 2

Special Population Dosing

Hemodialysis and Immunocompromised Adults (≥20 years)

Critical dosing difference—standard doses are inadequate:

  • Recombivax HB: 40 μg (1.0 mL) per dose in a 3-dose schedule at 0,1, and 6 months 1, 3
  • Engerix-B: 40 μg (2.0 mL) per dose in a 4-dose schedule at 0,1,2, and 6 months 1, 2
  • The 4-dose Engerix-B regimen achieves 67% seroprotection in hemodialysis patients 2
  • Annual anti-HBs testing is required with booster doses when levels fall below 10 mIU/mL 3

Pregnant Women

  • Only use: Engerix-B, Recombivax HB, or Twinrix 1, 3
  • Do NOT use: Heplisav-B or PreHevbrio due to insufficient safety data in pregnancy 1, 3

Infants Born to HBsAg-Positive Mothers

  • First dose within 12 hours of birth plus HBIG, then at 1-2 months and 6 months 3
  • The final dose must not be administered before 24 weeks of age 3

Alternative Schedules

Accelerated Protection Schedule (Engerix-B)

  • 0,1,2, and 12 months: Provides earlier seroprotection but requires a fourth dose at 12 months for long-term protection 1, 4
  • After dose at month 2, GMT is only 53 IU/L, but a fourth dose at month 12 produces robust booster response 4

Twinrix (Combined Hepatitis A and B)

  • Standard: 3 doses at 0,1, and 6 months (hepatitis B component is 20 μg per 1.0 mL) 1
  • Accelerated: 4 doses at 0 days, 7 days, 21-30 days, and 12 months 1, 3

Critical Dosing Intervals

Minimum intervals that must be respected:

  • Between doses 1 and 2: 4 weeks minimum 5, 3
  • Between doses 2 and 3: 8 weeks minimum 5, 3
  • Between doses 1 and 3: 16 weeks minimum 5, 3
  • Doses given ≤4 days before the minimum interval are considered valid 5, 3

Interrupted Schedules

Never restart the series if interrupted—simply continue where you left off 5, 3

  • If interrupted after dose 1, give dose 2 as soon as possible, then dose 3 at least 8 weeks after dose 2 5
  • If only dose 3 is delayed, administer it as soon as possible 5
  • Increasing intervals between doses has little effect on final immunogenicity and may actually increase antibody titers 3

Common Pitfalls to Avoid

  • Do not use standard adult doses (10-20 μg) in hemodialysis patients—they require 40 μg doses 1, 3
  • Do not give the third dose before 16 weeks from the first dose, even if 8 weeks have passed since the second dose 3
  • Do not give the final infant dose before 24 weeks of age, as this may compromise long-term immunity 3
  • Do not use Heplisav-B or PreHevbrio in pregnant women, children, or hemodialysis patients 1, 3
  • Do not restart the series if interrupted—this wastes doses and delays protection 5, 3

Age-Related Response Considerations

  • Adults over 40 years have lower seroconversion rates and lower GMTs (610 mIU/mL vs. higher in younger adults) 2
  • After dose 1, only 30-55% achieve protective levels; after dose 2,75%; after dose 3, >90% with traditional vaccines 3
  • Vaccine-induced immunity persists for >30 years 3

References

Guideline

Hepatitis B Vaccine Dosing and Schedule Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hepatitis B Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.